Research Support
Grant: #Knopp/AmRad/NCI Investigators:Knopp, Michael 03-01-2023 -02-29-2024 National Cancer Institute Yr 4: Imaging & radiation oncology core - co-director imaging Role:PI 1821623.00 Hold Level:Federal
Grant: #Master Investigators:Knopp, Michael 03-01-2023 -08-31-2024 National Cancer Institute Master Agreement - Knopp - Leidos, Inc. Role:PI 0.00 Hold Level:Federal
Grant: #AFT-32 Investigators:Knopp, Michael 03-01-2023 -12-31-2024 National Cancer Institute A Phase II study of palbociclib (PD-033299) in combination with ibrutinib in patient with previously treated mantle cell lymphoma Role:PI 62897.19 Hold Level:Federal
Grant: #SWO(THF)-1 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 The Hope Foundation for Cancer Research Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors):A Randomized Phase II Trial f Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small CellLungCaner Role:PI 25000.00 Hold Level:Non Profit
Grant: #SWO(THF)-2 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 The Hope Foundation for Cancer Research S1400 A biomarker driven master protocol for previously treated patients with squamous cell lung cancer (Lung-Map) Role:PI 50000.00 Hold Level:Non Profit
Grant: #SWO(THF)-3 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 The Hope Foundation for Cancer Research A Phase III randomized trial comparing high dose interferon to MK-3475 (Pembrolizumab) in patients with high risk resected melanoma Role:PI 70000.00 Hold Level:Non Profit
Grant: #SWO(THF)-4 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 The Hope Foundation for Cancer Research Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer Role:PI 125000.00 Hold Level:Non Profit
Grant: #SWO(THF)-5 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 The Hope Foundation for Cancer Research A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#738608) SBRT versus SBRT Alone in High Risk, Early Stage NSCLC Role:PI 125000.00 Hold Level:Non Profit
Grant: #AFT-38 Investigators:Knopp, Michael 03-01-2023 -12-31-2023 National Cancer Institute PATINA study (AFT-38) services Role:PI 350000.00 Hold Level:Federal
Grant: #A021602 Investigators:Knopp, Michael 03-01-2023 -12-31-2024 Alliance Foundation Trials, LLC A randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus Role:PI 150000.00 Hold Level:Non Profit
Grant: #A091105 Investigators:Knopp, Michael 03-01-2023 -12-31-2024 Bayer AG A phase III, double blind, randomized, placebo-controlled trial of sorafenib in desmoid tumors or aggressive fibromatosis (DT/DF) Role:PI 51936.64 Hold Level:Industry
Grant: #OHSU (U10CA180888) Investigators:Knopp, Michael 03-01-2023 -02-28-2025 National Cancer Institute SWOG Network Group Operations Center of the NCTN Role:PI 108971.00 Hold Level:Federal
Grant: #FDABAA-22-00123 Investigators:Knopp, Michael 09-30-2022 -09-29-2026 Food and Drug Administration Real World Collection of Radiographic Images and Treatment-Emergent Adverse Event Data: Next Phase Development of ICAREdata Research Infrastructure Role:PI 300000.00 Hold Level:Federal
Grant: #A021202 IROC Investigators:Knopp, Michael 08-01-2023 -06-30-2025 GlaxoSmithKline PLC (United Kingdom) Prospective randomized phase II trial of pazopanib (NSC #737754, IND 75648) versus placebo in patients with progressive carcinoid tumors Role:PI 0.00 Hold Level:Industry
Grant: #A021901 Investigators:Knopp, Michael 08-01-2023 -06-30-2025 Novartis AG Randomized phase II trial of 177Lu-DOTATATE versus everolimus in somatostatin receptor positive bronchial neuroendocrine tumors Role:PI 0.00 Hold Level:Industry
Grant: #SWOG S1826 Investigators:Knopp, Michael 09-01-2023 -08-31-2026 National Cancer Institute S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 yrs) w/ Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Role:PI 550343.00 Hold Level:Federal
Grant: #AFT Master Investigators:Knopp, Michael 10-01-2023 -09-30-2028 Alliance Foundation Trials, LLC AFT Master Agreement (Knopp) Role:PI 0.00 Hold Level:Non Profit
Grant: #AFT A021502 Investigators:Knopp, Michael 08-01-2023 -07-31-2026 National Cancer Institute Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (A021502) Role:PI 573100.00 Hold Level:Federal
Grant: #PHI COG Master Agreement Investigators:Knopp, Michael 08-01-2024 -07-31-2029 National Cancer Institute Public Health Institute - COG Master Agreement (Knopp) Role:PI 0.00 Hold Level:Federal
Grant: #AR70328 (UM1CA228823) Investigators:Knopp, Michael; Wright, Chad 08-01-2023 -07-31-2024 Public Health Institute COG Phase 1 (SP0285_001 IROC Services for PEP-CTN) Role:PI 75000.00 Hold Level:Non Profit
Grant: #AFT-15 Investigators:Knopp, Michael 06-17-2024 -03-10-2029 Alliance Foundation Trials, LLC A Phase I Study of Ibrutinib (PCI-32765) in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15) Role:PI 0.00 Hold Level:Non Profit
Grant: #SP0235 A031501/MK-3475 Investigators:Knopp, Michael 03-01-2023 -02-28-2027 Alliance for Clinical Trials in Oncology Foundation Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation (A031501) Role:PI 479600.00 Hold Level:Non Profit